Aspirin Inhibits Colon Cancer Cell and Tumor Growth and Downregulates Specificity Protein (Sp) Transcription Factors
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Acetylsalicylic acid (aspirin) is highly effective for treating colon cancer patients postdiagnosis; however, the mechanisms of action of aspirin in colon cancer are not well defined. Aspirin and its major metabolite sodium salicylate induced apoptosis and decreased colon cancer cell growth and the sodium salt of aspirin also inhibited tumor growth in an athymic nude mouse xenograft model. Colon cancer cell growth inhibition was accompanied by downregulation of Sp1, Sp3 and Sp4 proteins and decreased expression of Sp-regulated gene products including bcl-2, survivin, VEGF, VEGFR1, cyclin D1, c-MET and p65 (NFκB). Moreover, we also showed by RNA interference that β-catenin, an important target of aspirin in some studies, is an Sp-regulated gene. Aspirin induced nuclear caspase-dependent cleavage of Sp1, Sp3 and Sp4 proteins and this response was related to sequestration of zinc ions since addition of zinc sulfate blocked aspirin-mediated apoptosis and repression of Sp proteins. The results demonstrate an important underlying mechanism of action of aspirin as an anticancer agent and, based on the rapid metabolism of aspirin to salicylate in humans and the high salicylate/aspirin ratios in serum, it is likely that the anticancer activity of aspirin is also due to the salicylate metabolite.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136 · cited 3×
“Aspirin and other NSAIDs reduce the incidence and increase survival of colon cancer patients and similar results have been observed for aspirin as a chemotherapeutic agent for treatment of breast cancer patients [4–8].”
BackgroundResultAspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557 · cited 3×
“Other drugs including NSAIDs such as tolfenamic acid and COX-2 inhibitors also inhibit cancer cell growth and downregulate Sp transcription factors [18–26] and, in this study, we have investigated the effects of aspirin on Sp proteins and other Sp-regulated genes including b-catenin.”
BackgroundInfluentialAspirin Intake and Survival After Breast Cancer
Holmes, M. D., Chen, W. Y., Li, L., Hertzmark, E., Spiegelman, D., & Hankinson, S. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7918 · Cited by 365 · cited 3×
“Aspirin and other NSAIDs reduce the incidence and increase survival of colon cancer patients and similar results have been observed for aspirin as a chemotherapeutic agent for treatment of breast cancer patients [4–8].”
BackgroundResultA Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence
Jacobs, E. J., Thun, M. J., Bain, E. B., Rodriguez, C., Henley, S. J., & Calle, E. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk132 · Cited by 322 · cited 2×
“Aspirin and other NSAIDs reduce the incidence and increase survival of colon cancer patients and similar results have been observed for aspirin as a chemotherapeutic agent for treatment of breast cancer patients [4–8].”
BackgroundResultChintharlapalli, S., Papineni, S., Ramaiah, S. K., & Safe, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3735 · Cited by 297 · cited 1×
“Moreover, several anticancer agents including NSAIDs and GT-094 (a NO-NSAID), curcumin, betulinic acid and synthetic triterpenoids, and arsenic trioxide decrease expression of Sp1, Sp3, Sp4 and Sp-regulated genes in cancer cells and these effects contribute to their anticancer activity [17,18,20,35].”
BackgroundSelf-citationEffect of aspirin and NSAIDs on risk and survival from colorectal cancer
Din, F. V. N., Theodoratou, E., Farrington, S. M., Tenesa, A., Barnetson, R. A., Cetnarskyj, R., Stark, L., Porteous, M. E., Campbell, H., & Dunlop, M. G. (2010) · Gut · doi:10.1136/gut.2009.203000 · Cited by 284 · cited 1×
“A recent report on the chemopreventive effects of aspirin showed that the incidence of colon cancer in Scotland was significantly decreased in the general population at the lowest daily dose of aspirin (75 mg) and the decreased incidence was observed even after only 5 yr of aspirin use [7].”
BackgroundAspirin, salicylates, and cancer
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A., & Morgan, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60243-9 · Cited by 282 · cited 4×
“Based on the similar effects of aspirin and salicylate as anticancer agents observed in Figures 1, 2, 3 and other studies [3,10,11,40] and the high serum salicylate/aspirin ratios [27], the cancer chemotherapeutic effects of aspirin observed in human cancer studies [3–5,7,8] may primarily be due to the salicylate meta…”
BackgroundResultInfluentialAbdelrahim, M., Smith, R., Burghardt, R., & Safe, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0713 · Cited by 199 · cited 2×
“RNA interference studies in several cancer cell lines show that knockdown of Sp1, Sp3 and Sp4 (singly or in combination) results in decreased expression of growth promoting (EGFR, c-MET, cyclin D1), survival (bcl-2, survivin), angiogenic (VEGF and its receptors), and pro-inflammatory [p65 (NFkB)] genes or gene product…”
BackgroundSelf-citationJutooru, I., Chadalapaka, G., Lei, P., & Safe, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.095240 · Cited by 178 · cited 8×
“Previous studies by RNA interference (RNAi) show that both survivin and bcl-2 are regulated by Sp1, Sp3 and Sp4 in cancer cells [17,22,24–26].”
BackgroundResultInfluentialSelf-citationTolfenamic Acid and Pancreatic Cancer Growth, Angiogenesis, and Sp Protein Degradation
Abdelrahim, M., Baker, C. H., Abbruzzese, J. L., & Safe, S. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj232 · Cited by 174 · cited 1×
“Moreover, several anticancer agents including NSAIDs and GT-094 (a NO-NSAID), curcumin, betulinic acid and synthetic triterpenoids, and arsenic trioxide decrease expression of Sp1, Sp3, Sp4 and Sp-regulated genes in cancer cells and these effects contribute to their anticancer activity [17,18,20,35].”
BackgroundSelf-citationCurcumin Decreases Specificity Protein Expression in Bladder Cancer Cells
Chadalapaka, G., Jutooru, I., Chintharlapalli, S., Papineni, S., Smith, R., Li, X., & Safe, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6805 · Cited by 170 · cited 4×
“5B) was less than observed in other cancer cell lines [22,25] and aspirin-induced inhibition of NFkB was only due, in part, to downregulation of Sp1, Sp3 and Sp4 transcription factors.”
BackgroundResultInfluentialSelf-citationChintharlapalli, S., Papineni, S., Lei, P., Pathi, S., & Safe, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-371 · Cited by 165 · cited 2×
“Dithiothretol (DTT) (98”
ResultSelf-citationEpidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer
Baron, J. A. (2003) · Progress in Experimental Tumor Research · doi:10.1159/000071364 · Cited by 161 · cited 2×
“concern regarding the adverse gastrointestinal side-effects of aspirin [2,3,34] and in the future, these may be circumvented by using NO-NSAIDs.”
BackgroundEffect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A
Bos, C. L., Kodach, L. L., van den Brink, G. R., Diks, S. H., van Santen, M. M., Richel, D. J., Peppelenbosch, M. P., & Hardwick, J. C. H. (2006) · Oncogene · doi:10.1038/sj.onc.1209658 · Cited by 156
Chimienti, F., Seve, M., Richard, S., Mathieu, J., & Favier, A. E. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00624-4 · Cited by 156 · cited 2×
“It has also been reported that zinc depletion induces apoptosis and decreases Sp1, Sp3 and Sp4 in cancer cell lines [32,33], and we confirmed that aspirin-induced PARP cleavage and downregulation of Sp1, Sp3 and Sp4 was inhibited in RKO and SW480 cells cotreated with aspirin plus ZnSO4 (Figs.”
BackgroundAspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
Langley, R. E., Burdett, S., Tierney, J. F., Cafferty, F., Parmar, M. K. B., & Venning, G. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.289 · Cited by 144 · cited 1×
“Acetylsalicylic acid or aspirin is a non-steroidal anti-inflammatory drug (NSAID) widely used for treatment of pain, fever and other inflammatory conditions [1] and the role of aspirin and other NSAIDs in cancer has been extensively investigated [2,3].”
BackgroundYurochko, A. D., Mayo, M. W., Poma, E. E., Baldwin, A. S., & Huang, E. S. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4638-4648.1997 · Cited by 143 · cited 1×
“Since NFkB (p65) and the b-catenin promoters contain GC-rich Sp binding sites [28,29], we used RNAi to determine the role of Sp1, Sp3 and Sp4 in regulation of p65, p50 and b-catenin in colon cancer cells.”
MethodStark, L. A., Reid, K., Sansom, O. J., Din, F. V., Guichard, S., Mayer, I., Jodrell, D. I., Clarke, A. R., & Dunlop, M. G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl220 · Cited by 135 · cited 6×
“4A and 4B) and these results differed with previous studies [13–15].”
BackgroundMethodResultInfluentialPiedrafita, F. J., & Pfahl, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6348 · Cited by 135 · cited 1×
“Arsenic trioxide also induced caspase-dependent cleavage of Sp3 and Sp4 in bladder cancer cells [26] and retinoid (CD437)-induced Sp1 degradation was also caspase-dependent in EL-4 cells [36].”
BackgroundAbdelrahim, M., & Safe, S. H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011825 · Cited by 134 · cited 1×
“Other drugs including NSAIDs such as tolfenamic acid and COX-2 inhibitors also inhibit cancer cell growth and downregulate Sp transcription factors [18–26] and, in this study, we have investigated the effects of aspirin on Sp proteins and other Sp-regulated genes including b-catenin.”
BackgroundSelf-citationChintharlapalli, S. R., Papineni, S., Abdelrahim, M., Abudayyeh, A., Jutooru, I., Chadalapaka, G., Wu, F., Mertens‐Talcott, S. U., Vanderlaag, K., Cho, S. D., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24530 · Cited by 133
Self-citationBorthwick, G. M., Johnson, A. S., Partington, M. W., Burn, J., Wilson, R., & Arthur, H. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-5987com · Cited by 122 · cited 3×
“For example, aspirin downregulates bcl-2 expression [9], inhibits vascular endothelial growth factor, exhibits antiangiogenic activity [10,11], and inhibits the WNT/b-catenin pathway [12].”
BackgroundResultPathi, S. S., Jutooru, I., Chadalapaka, G., Sreevalsan, S., Anand, S., Thatcher, G. R., & Safe, S. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0363 · Cited by 111 · cited 9×
“Mechanistic studies indicate that the anticancer activity of GT-094 is due, in part, to ROS-dependent downregulation of specificity protein (Sp) transcription factors Sp1, Sp3, Sp4 and Sp-regulated genes which include bcl-2, survivin, hepatocyte growth factor receptor (c-MET), VEGF and its receptor VEGFR1 [17].”
BackgroundResultInfluentialSelf-citationEvidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis
Din, F. V. N., Dunlop, M. G., & Stark, L. A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601913 · Cited by 102 · cited 6×
“4A and 4B) and these results differed with previous studies [13–15].”
BackgroundMethodResultInfluentialChadalapaka, G., Jutooru, I., Burghardt, R. C., & Safe, S. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0493 · Cited by 100 · cited 2×
“RNA interference studies in several cancer cell lines show that knockdown of Sp1, Sp3 and Sp4 (singly or in combination) results in decreased expression of growth promoting (EGFR, c-MET, cyclin D1), survival (bcl-2, survivin), angiogenic (VEGF and its receptors), and pro-inflammatory [p65 (NFkB)] genes or gene product…”
BackgroundSelf-citationTrace Elements in Man and Animals 10
Roussel, A. M., Favrier, A. E., & Anderson, R. A. (2002) · Springer eBooks · doi:10.1007/b100326 · Cited by 93
Genomic Organization of the Human β-Catenin Gene (CTNNB1)
Nollet, F., Berx, G., Molemans, F., & Roy, F. M. V. (1996) · Genomics · doi:10.1006/geno.1996.0136 · Cited by 92 · cited 1×
“Since NFkB (p65) and the b-catenin promoters contain GC-rich Sp binding sites [28,29], we used RNAi to determine the role of Sp1, Sp3 and Sp4 in regulation of p65, p50 and b-catenin in colon cancer cells.”
MethodJutooru, I., Chadalapaka, G., Abdelrahim, M., Basha, R. M., Samudio, I. J., Konopleva, M. Y., Andreeff, M., & Safe, S. H. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064451 · Cited by 92
Self-citationWang, Y.-T., Chuang, J., Shen, M., Yang, W., Chang, W., & Hung, J. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.05.043 · Cited by 83 · cited 1×
“Several pathways have been described for enhanced Sp degradation in cancer cell lines and these include activation of proteasomes, caspases and ROS [17–20,22–26] and also a pathway which involves nuclear export of Sp1 followed by proteolytic degradation in the cytosol [30].”
BackgroundJutooru, I., Chadalapaka, G., Sreevalsan, S., Lei, P., Barhoumi, R., Burghardt, R., & Safe, S. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.027 · Cited by 78 · cited 1×
“Arsenic trioxide also induced caspase-dependent cleavage of Sp3 and Sp4 in bladder cancer cells [26] and retinoid (CD437)-induced Sp1 degradation was also caspase-dependent in EL-4 cells [36].”
BackgroundSelf-citationKim, K. M., Song, J. J., An, J. Y., Kwon, Y. T., & Lee, Y. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503713200 · Cited by 66 · cited 1×
“For example, aspirin downregulates bcl-2 expression [9], inhibits vascular endothelial growth factor, exhibits antiangiogenic activity [10,11], and inhibits the WNT/b-catenin pathway [12].”
BackgroundMyths and facts in the use of anti-inflammatory drugs
Hunt, R. H., Lanas, A., Stichtenoth, D. O., & Scarpignato, C. (2009) · Annals of Medicine · doi:10.1080/07853890902887295 · Cited by 55 · cited 1×
“concern regarding the adverse gastrointestinal side-effects of aspirin [2,3,34] and in the future, these may be circumvented by using NO-NSAIDs.”
BackgroundShtivelband, M. I., Juneja, H., Lee, S., & Wu, K. K. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00446.x · Cited by 48 · cited 3×
“For example, aspirin downregulates bcl-2 expression [9], inhibits vascular endothelial growth factor, exhibits antiangiogenic activity [10,11], and inhibits the WNT/b-catenin pathway [12].”
BackgroundResultSelf-citationDin, F. V. N., Stark, L. A., & Dunlop, M. G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602455 · Cited by 42 · cited 1×
“Aspirin-induced downregulation of p65 expression is maximal after treatment for 48 hr, whereas previous studies showed that IkBa expression was observed as early as 6 hr after treatment [13].”
MethodHagos, G. K., Carroll, R. E., Kouznetsova, T., Li, Q., Toader, V., Fernandez, P. A., Swanson, S. M., & Thatcher, G. R. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0069 · Cited by 36 · cited 1×
“Ethyl 2-[(2,3-bis(nitrooxy)propyl)disulfanyl]benzoate (GT-094) is a synthetic nitro-non-steroidal anti-inflammatory drug (NONSAID) and like aspirin, GT-094 also inhibits colon cancer cell and tumor growth [16,17].”
BackgroundOlguı́n, H. J., Flores‐Pérez, J., Asseff, I. L., Abdalá, A. L., & Rodríguez, L. C. (2004) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.379 · Cited by 21
Kim, E. Y., Chang, S.-Y., Chung, J.-M., Ryu, B. R., Joo, C.-K., Moon, H.-S., Kang, K., Yoon, S.-H., Han, P., & Gwag, B. J. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0421 · Cited by 20 · cited 1×
“The physical interactions of zinc ions with aspirin have previously been observed [37], and functional interactions between zinc ions and aspirin in terms of zincinduced neurotoxicity and the fetal toxicity have also been reported [38,39].”
BackgroundGhezzo, F., Cesano, L., Mognetti, B., Pesce, E., Pirro, E., Corvetti, G., Berta, G. N., Zingaro, B., & Carlo, F. D. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.3.697 · Cited by 14 · cited 2×
“Based on the similar effects of aspirin and salicylate as anticancer agents observed in Figures 1, 2, 3 and other studies [3,10,11,40] and the high serum salicylate/aspirin ratios [27], the cancer chemotherapeutic effects of aspirin observed in human cancer studies [3–5,7,8] may primarily be due to the salicylate meta…”
BackgroundResultStudies on the metal-complex of acetyl salicylic acid (aspirin)
Baslas, R. K., Zamani, R., & Nomani, A. A. (1979) · Cellular and Molecular Life Sciences · doi:10.1007/bf01922702 · Cited by 13 · cited 1×
“The physical interactions of zinc ions with aspirin have previously been observed [37], and functional interactions between zinc ions and aspirin in terms of zincinduced neurotoxicity and the fetal toxicity have also been reported [38,39].”
BackgroundInfluence of maternal drug metabolism on the fetal toxicity induced by acetylsalicylic acid.
SAITO, H., Sakai, T., Ueno, K., & Kitagawa, H. (1982) · The Journal of Toxicological Sciences · doi:10.2131/jts.7.177 · Cited by 5 · cited 1×
“The physical interactions of zinc ions with aspirin have previously been observed [37], and functional interactions between zinc ions and aspirin in terms of zincinduced neurotoxicity and the fetal toxicity have also been reported [38,39].”
BackgroundMichel, S., Chimienti, F., Richard, S., Jacques, M., & Favier, A. E. (2002) · Springer eBooks · doi:10.1007/0-306-47466-2_309 · Cited by 1
Cited by
Sp1 and the ‘hallmarks of cancer’
Beishline, K., & Azizkhan‐Clifford, J. (2015) · The FEBS Journal · doi:10.1111/febs.13148 · Cited by 524
Sp1 transcription factor: A long-standing target in cancer chemotherapy
Vizcaíno, C., Mansilla, S., & Portugal, J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.008 · Cited by 377
Molecular targets of aspirin and cancer prevention
Alfonso, L., Ai, G., Spitale, R. C., & Bhat, G. J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.271 · Cited by 222
Plano, D., Karelia, D. N., Pandey, M. K., Spallholz, J. E., Amin, S., & Sharma, A. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01503 · Cited by 186
FOXG1 promotes aging inner ear hair cell survival through activation of the autophagy pathway
He, Z., Li, M., Fang, Q., Liao, F.-L., Zou, S., Wu, X., Sun, H., Zhao, X., Hu, Y., Xu, X., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1916194 · Cited by 154
Metadata
- Authors
- Pathi, S., Jutooru, I., Chadalapaka, G., Nair, V., Lee, S.-O., & Safe, S.
- Affiliations
- Texas A&M University (US)
- Texas A&M Health Science Center (US)
- Corresponding author
- Safe, Stephen
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-26
- Volume
- 7
- Issue
- 10
- Pages
- e48208
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3482208
- OpenAlex
- W1968810018
- Cited by
- 127
- References
- 41
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 11 · 2017: 13 · 2016: 16 · 2015: 17 · 2014: 11 · 2013: 9
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OakTrust (Texas A&M University Libraries) (submittedVersion)
- Funders
- Texas AgriLife Research
- National Institutes of Health
- National Cancer Institute (R01CA136571)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- aspirin, colon cancer, specificity proteins, Sp1, Sp3, Sp4, salicylates, apoptosis, zinc ions, β-catenin, NF-κB, Bcl-2, survivin, vascular endothelial growth factor, c-Met, cyclin D1, tumor growth inhibition, anticancer mechanism
- MeSH terms
- Animals, Aspirin, Colonic Neoplasms, Female, Humans, Mice, Nude, Gene Expression Regulation, Neoplastic, Sp1 Transcription Factor, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Sp Transcription Factors, Sp3 Transcription Factor, Sp4 Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.